Factors associated with late antiretroviral therapy initiation among adults in Mozambique - Wikidata - awgldk - TriplyDB

Factors associated with late antiretroviral therapy initiation among adults in Mozambique

Factors associated with late antiretroviral therapy initiation among adults in Mozambique

http://www.wikidata.org/entity/Q34277766

about

Home visits during pregnancy enhance male partner HIV counselling and testing in Kenya: a randomized clinical trial Trends in and correlates of CD4+ cell count at antiretroviral therapy initiation after changes in national ART guidelines in Rwanda.Trends in baseline CD4 cell counts and risk factors for late antiretroviral therapy initiation among HIV-positive patients in Shanghai, a retrospective cross-sectional study.Exploratory Analysis of Time from HIV Diagnosis to ART Start, Factors and effect on survival: A longitudinal follow up study at seven teaching hospitals in Ethiopia.Comprehensiveness of HIV care provided at global HIV treatment sites in the IeDEA consortium: 2009 and 2014.Trends and outcomes of late initiation of combination antiretroviral therapy driven by late presentation among HIV-positive Taiwanese patients in the era of treatment scale-up.Health benefits, costs, and cost-effectiveness of earlier eligibility for adult antiretroviral therapy and expanded treatment coverage: a combined analysis of 12 mathematical models.Poor clinical outcomes for HIV infected children on antiretroviral therapy in rural Mozambique: need for program quality improvement and community engagement Characteristics and comprehensiveness of adult HIV care and treatment programmes in Asia-Pacific, sub-Saharan Africa and the Americas: results of a site assessment conducted by the International epidemiologic Databases to Evaluate AIDS (IeDEA) Colla Reviewing progress: 7 year trends in characteristics of adults and children enrolled at HIV care and treatment clinics in the United Republic of Tanzania.Bacteremia as a cause of fever in ambulatory, HIV-infected Mozambican adults: results and policy implications from a prospective observational study.Trends of CD4 cell count levels at the initiation of antiretroviral therapy over time and factors associated with late initiation of antiretroviral therapy among Asian HIV-positive patients.Implementation and operational research: Integrated pre-antiretroviral therapy screening and treatment for tuberculosis and cryptococcal antigenemia Advanced disease at enrollment in HIV care in four sub-Saharan African countries: change from 2006 to 2011 and multilevel predictors in 2011.Cotrimoxazole prophylaxis and antiretroviral therapy: an observational cohort study in China.Characteristics and outcomes of adult Ethiopian patients enrolled in HIV care and treatment: a multi-clinic observational study.Late presentation for diagnosis of HIV infection among HIV positive patients in South Tigray Zone, Ethiopia The clock is ticking: the rate and timeliness of antiretroviral therapy initiation from the time of treatment eligibility in Kenya.Determinants of late presentation to HIV/AIDS care in Southern Tigray Zone, Northern Ethiopia: an institution based case-control study.The problem of late ART initiation in Sub-Saharan Africa: a transient aspect of scale-up or a long-term phenomenon?Factors associated with loss to clinic among HIV patients not yet known to be eligible for antiretroviral therapy (ART) in Mozambique Gender-related differences in outcomes and attrition on antiretroviral treatment among an HIV-infected patient cohort in Zimbabwe: 2007-2010.Insights into Adherence among a Cohort of Adolescents Aged 12-20 Years in South Africa: Reported Barriers to Antiretroviral Treatment.Advanced HIV disease at entry into HIV care and initiation of antiretroviral therapy during 2006-2011: findings from four sub-saharan African countries.Antiretroviral treatment in low-resource settings: what has changed in the last 10 years and what needs to change in the coming years?CD4 Decay Rate as an Indicator of the Time Interval between Initial Infection and First Diagnosis among Drug-Naïve Human Immunodeficiency Virus Seropositive Individuals in Lagos, Nigeria.Management of fever in ambulatory HIV-infected adults in resource-limited settings: prospective observational evaluation of a new Mozambican guideline.The status of adolescent medicine: building a global adolescent workforce.Tenofovir stock shortages have limited impact on clinic- and patient-level HIV treatment outcomes in public sector clinics in South Africa.ART Adherence as a Key Component of Prevention With Persons Living With HIV in Mozambique.Advanced Human Immunodeficiency Virus Disease at Diagnosis in Mozambique and Swaziland.Barriers to antiretroviral treatment initiation in rural KwaZulu-Natal, South Africa.Reply to Patten et al.Failure to initiate HIV treatment in patients with high CD4 counts: evidence from demographic surveillance in rural South Africa.'Test and Treat' Among Women at High Risk for HIV-infection in Kampala, Uganda: Antiretroviral Therapy Initiation and Associated Factors.Trends, treatment outcomes, and determinants for attrition among adult patients in care at a large tertiary HIV clinic in Nairobi, Kenya: a 2004–2015 retrospective cohort study.Effective linkage from point of HIV testing to care and treatment in Tanga region, Tanzania

P2860

Q28649558-880FB55B-A00D-402F-B39B-2D65340650D9 Q30388278-8161818E-E1D5-45ED-B70A-D5B65FD9D200 Q33576831-44E956C4-32E5-4249-A9C3-637FFA8B0F4C Q33596135-32B907C2-497B-4266-A72B-B711F2D4E03E Q33777533-7152178D-CBC7-4D83-A511-94C78EACF011 Q33859987-F987F2F0-0C0D-42BC-BD81-505E8557642E Q33966505-72066555-1DDC-4503-ABAD-7DEA1F74F73E Q34374033-3DEB8D34-B14B-4723-A930-83B41C84DC8E Q34718675-1723C555-D373-48D6-B507-460AD5A26F9B Q35026559-A04727C9-29BF-4989-B3AC-FCABCA1EC381 Q35080484-1FE31D29-1AA0-4239-A2AA-A06D8310006D Q35111937-600BC4C5-BF91-430E-9AC7-CDB20B629D89 Q35170385-CF1A001A-D61B-4FAA-B169-309C6F06FA13 Q35180760-EF0CA4BA-C490-468D-A5A4-CF5687F19955 Q35211308-1E340D46-6AA4-48E0-860F-637B37D3EC51 Q35620659-A7E51C76-E1DD-4735-990E-244B31ABBA00 Q36074135-B7EF9949-7989-44E8-87CB-0971B5CD41C5 Q36215535-D24DFAEA-D023-4642-9B10-EE95E2826954 Q36341103-3E0B4128-FED3-46F0-8568-0FC10B9C3CDF Q36848380-30EAFF66-58B3-4E69-8246-75A354CDDF53 Q36920997-DD9594EA-704E-47E3-BED1-D9E4E100B7A4 Q37354318-29F97EA3-5D1D-4D1D-A9EB-BFEEC54FC001 Q37404721-1B8A7A4A-EE9E-47CF-BA1C-0C7AF5A0279E Q37473041-D423F449-34CA-4080-8D43-928DAB622FA0 Q38067503-8803F124-2D4F-4286-BF84-D8081F9C99AD Q38405864-B25CA73C-1B41-482E-BCEC-CEA871368F48 Q38433074-A0336D23-8B43-4794-B1D3-5FF5AC02E74F Q38545957-98C61627-DFC0-49BF-9F32-A7F6A03BFB68 Q39174707-C514AF75-C1CE-4DB7-9405-7CB49AF26FCB Q40916593-357B10A8-4E90-40D1-A82D-A000F485533A Q41676901-3A1C2E1C-A4C4-420E-A10F-B88D9194997C Q46139842-E2E77819-C9D8-4D75-9EAB-C432F0C309C2 Q46234831-5B639FB6-4F87-4412-980C-3490F3CE3122 Q47210806-FC1F761C-9FB4-4B62-915B-5A4069F6CEB9 Q47614870-CC4A04F0-1015-406A-80D5-830023BECB92 Q55475729-DC7DDEBB-DBDA-4C7B-BCB2-E48EDC94375C Q58775181-C7B7BA6A-6D46-46EB-AB97-C3442C909E6F

P2860

Factors associated with late antiretroviral therapy initiation among adults in Mozambique

http://www.wikidata.org/entity/Q34277766

description

2012 nî lūn-bûn

@nan

2012 թուականի Մայիսին հրատարակուած գիտական յօդուած

@hyw

2012 թվականի մայիսին հրատարակված գիտական հոդված

@hy

2012年の論文

@ja

2012年論文

@yue

2012年論文

@zh-hant

2012年論文

@zh-hk

2012年論文

@zh-mo

2012年論文

@zh-tw

2012年论文

@wuu

name

Factors associated with late antiretroviral therapy initiation among adults in Mozambique

@ast

Factors associated with late antiretroviral therapy initiation among adults in Mozambique

@en

Factors associated with late antiretroviral therapy initiation among adults in Mozambique

@nl

type

label

Factors associated with late antiretroviral therapy initiation among adults in Mozambique

@ast

Factors associated with late antiretroviral therapy initiation among adults in Mozambique

@en

Factors associated with late antiretroviral therapy initiation among adults in Mozambique

@nl

prefLabel

Factors associated with late antiretroviral therapy initiation among adults in Mozambique

@ast

Factors associated with late antiretroviral therapy initiation among adults in Mozambique

@en

Factors associated with late antiretroviral therapy initiation among adults in Mozambique

@nl

P1433

Q34277766-2B4B9299-AE86-434A-8CFE-BA89171A2FC6

P1476

Q34277766-76B317DD-19F0-4CBD-AD4B-0D98CAC21964

P2093

Q34277766-216FE6A3-6270-43EF-8C58-1A5EA3FCA498

Q34277766-26C23351-7E48-49CD-BABF-5103FFA5E883

Q34277766-64687692-AC2D-42A2-A60B-752C5900B6AB

Q34277766-76BFA7F6-5505-45F3-87BF-75B6EF29207A

Q34277766-9243E8A1-1EED-4A06-BBFC-55A31655B511

Q34277766-D8DCBA37-8CCE-4EB5-A775-11DF0CC2A3DF

Q34277766-F0C7DDAB-7CFE-43F4-B76E-55C5ABD36A79

P2860

Q34277766-02B1E54F-36B6-4FB6-84DD-C4DA4418F167

Q34277766-13A282E8-DE08-408F-B120-52189764EAFF

Q34277766-13F9FECE-AADE-4456-8427-82233291245B

Q34277766-13FEEF87-C77C-4F69-81E6-5BA34FB27EE3

Q34277766-1636FF2F-9F52-4C74-A96D-8998AE760F00

Q34277766-1A7C1C35-5FC6-403E-A2DB-0E5F401AB4E3

Q34277766-22D3BA56-B435-481C-9F76-05826BC74450

Q34277766-22DD2FB5-ABB3-4DC8-8E48-5B7DB8C10C98

Q34277766-3E74B4B9-F9FE-49FB-BEA0-60E762D315EF

Q34277766-43CA0388-2D2A-4F2B-A9EE-5ADFA2575BBE

P304

Q34277766-C7348E9A-15FD-45C2-9809-CA1685E0F6BC

P31

Q34277766-AF5705B1-48B9-458D-B4A5-3B8577FFC0C4

P356

Q34277766-CD5C3C76-299E-4EDF-8F4C-54B859203DA6

P407

Q34277766-24C84D72-3FD2-4668-AA48-C8F3CB96456E

P433

Q34277766-3FCBFA31-2BC6-4FBD-B692-68ED758DAE2C

P478

Q34277766-B9D801B3-57B8-438B-8F12-8DC11FD0EDAF

P50

Q34277766-43624C00-FF98-47EE-9D57-469E8A4F3E66

Q34277766-75BAEBEE-43B3-47A6-BEEE-50EFEA72865E

Q34277766-D7E62303-AB4C-4FB6-A90B-E11146CED836

Q34277766-E8C7C865-34EA-42AB-B8A2-94D3B571B3E1

P577

Q34277766-A0320437-C37E-4A45-B065-1EBE3C6CD303

P5875

Q34277766-D80BFC9A-B9E2-4DDB-B519-CD161F67A3AA

P698

Q34277766-C3406F54-F4C7-441E-B3BF-02C852520D34

P921

Q34277766-0A8E9033-0898-4D75-B152-5847037CA6B3

Q34277766-639FEE88-771A-4242-AC45-C00DDDBA7DE7

P932

Q34277766-BBE4A072-E26C-4CC9-8722-52A0A5D9A4E8

P356

JOURNAL.PONE.0037125

P1433

P1476

Factors associated with late antiretroviral therapy initiation among adults in Mozambique

@en

P2093

Americo Assan

http://www.w3.org/2001/XMLSchema#string

David Hoos

http://www.w3.org/2001/XMLSchema#string

Josue Lima

http://www.w3.org/2001/XMLSchema#string

Maria Fernanda Alvim

http://www.w3.org/2001/XMLSchema#string

Maria Lahuerta

http://www.w3.org/2001/XMLSchema#string

Mie Okamura

http://www.w3.org/2001/XMLSchema#string

Rufino Fernandes

http://www.w3.org/2001/XMLSchema#string

P2860

The spread, treatment, and prevention of HIV-1: evolution of a global pandemic

Mortality of HIV-infected patients starting antiretroviral therapy in sub-Saharan Africa: comparison with HIV-unrelated mortality

Uptake of workplace HIV counselling and testing: a cluster-randomised trial in Zimbabwe.

Late-disease stage at presentation to an HIV clinic in the era of free antiretroviral therapy in Sub-Saharan Africa

Five-year outcomes of initial patients treated in Botswana's National Antiretroviral Treatment Program.

Four-year treatment outcomes of adult patients enrolled in Mozambique's rapidly expanding antiretroviral therapy program.

Retention in care among HIV-infected patients in resource-limited settings: emerging insights and new directions.

Rapid scale-up of antiretroviral therapy at primary care sites in Zambia: feasibility and early outcomes.

Revised recommendations for HIV testing of adults, adolescents, and pregnant women in health-care settings.

Predictors of successful early infant diagnosis of HIV in a rural district hospital in Zambézia, Mozambique

P304

e37125

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1371/JOURNAL.PONE.0037125

http://www.w3.org/2001/XMLSchema#string

P407

P433

5

http://www.w3.org/2001/XMLSchema#string

P478

7

http://www.w3.org/2001/XMLSchema#string

P50

Harriet Nuwagaba-Biribonwoha

P577

2012-05-15T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

225030160

http://www.w3.org/2001/XMLSchema#string

P698

22615917

http://www.w3.org/2001/XMLSchema#string

P921

antiretroviral drug

P932

3352894

http://www.w3.org/2001/XMLSchema#string